Homozygous Familial Hypercholesterolemia

Disease

Related News

LIB Therapeutics launches Lerochol in the United States after FDA approval

May 11, 2026

LIB Therapeutics launched Lerochol in the United States after FDA approval for lowering LDL-C in adults with hypercholesterolemia, including HeFH. The once-monthly PCSK9 inhibitor is available with a $199-per-month cash-pay option.

Ultragenyx Reports Q4 2025 Results, Resubmits UX111 Gene Therapy Application to FDA

Feb 13, 2026

Ultragenyx reported Q4 2025 revenues of $207 million, up 25% year-over-year, while announcing a 10% workforce reduction and resubmission of its UX111 gene therapy application following positive long-term clinical data.